Stock info Halozyme Therapeutics | Filter  Basic-Info

Halozyme Therapeutics

The company mostly operates in the biotech sector. The period from 2006 till the end of 2016 the international sector gained around 59 percent. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-2016) there is a minus of 59 percent.

The past year was a good investment year for Halozyme Therapeutics investors

Over the past year the company' stock lost around 30 percent. Halozyme Therapeutics' stock rose the past 5 years at around 24 percent. Halozyme Therapeutics's revenues between 2011 and 2015 were very volatile and moved between 42,33 million dollars and 135,06 million dollars. Halozyme Therapeutics's net incomes between 2011 and 2015 were very volatile through the time and moved between -19,77 million dollars and -32,23 million dollars.

The American company didn't pay out any dividends (in the past 5 years).

Halozyme Therapeutics' balance mostly financed with equity

At the end of 2015 the biotech company's balance sheet was worth 181,79 million dollars. At the end of 2015 the total debt positon equaled 138,79 million dollars. This is around 76,35 percent of the total balance sheet. Last year the biotech company's price/earnings-ratio (PE) was around -39. So the investors valued the stock at -39 times 2015' earnings per share. Based on the classical stock valuation theories the American stock can be seen as a growth stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 2,15 billion dollars. At the end of 2015 around 126,7 million stocks were listed.

All the annual reports of Halozyme Therapeutics are available here. More information about Halozyme Therapeutics can be found it's website. .